nisoxetine has been researched along with Hypertension, Pulmonary in 1 studies
nisoxetine: potent inhibitor for norepinephrine uptake into rat brain synaptosomes & brain; NM refers to (+-)-isomer; RN given refers to parent cpd; structure
nisoxetine : A secondary amino compound that is N-methyl-3-phenylpropan-1-amine substituted at position 3 by a 2-methoxyphenoxy group.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment of rats with monocrotaline (MCT) leads to pulmonary hypertension, right ventricular (RV) hypertrophy, and finally to RV heart failure." | 3.71 | Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure. ( Beilfuss, A; Brandt, K; Brodde, OE; Heinroth-Hoffmann, I; Leineweber, K; Pönicke, K; Wludyka, B, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Leineweber, K | 1 |
Brandt, K | 1 |
Wludyka, B | 1 |
Beilfuss, A | 1 |
Pönicke, K | 1 |
Heinroth-Hoffmann, I | 1 |
Brodde, OE | 1 |
1 other study available for nisoxetine and Hypertension, Pulmonary
Article | Year |
---|---|
Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure.
Topics: Animals; Binding, Competitive; Cell Membrane; Disease Models, Animal; Eye Proteins; Fluoxetine; G-Pr | 2002 |